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Prosper Okonkwo,3 and Phyllis Kanki1
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Background. Most evaluations of loss to follow-up (LTFU) in human immunodeﬁciency virus (HIV) treatment
programs focus on baseline predictors, prior to antiretroviral therapy (ART) initiation. As risk of LTFU is a contin-
uous issue, the aim of this evaluation was to augment existing information with further examination of time-dependent
predictors of loss.
Methods. This was a retrospective evaluation of data collected between 2004 and 2012 by the Harvard School of
Public Health and the AIDS Prevention Initiative in Nigeria as part of PEPFAR-funded program in Nigeria. We used
multivariate modeling methods to examine associations between CD4+ cell counts, viral load, and early adherence pat-
terns with LTFU, deﬁned as no reﬁlls collected for at least 2 months since the last scheduled appointment.
Results. Of 51 953 patients initiated on ART between 2004 and 2011, 14 626 (28%) were LTFU by 2012. Factors
associated with increased risk for LTFU were young age, having nonincome-generating occupations or no education,
being unmarried, World Health Organization (WHO) stage, having a detectable viral load, and lower CD4+ cell counts.
In a subset analysis, adherence patterns during the ﬁrst 3 months of ARTwere associated with risk of LTFU bymonth 12.
Conclusions. In settings with limited resources, early adherence patterns, as well as CD4+ cell counts and unsup-
pressed viral load, at any time point in treatment are predictive of loss and serve as effective markers for developing
targeted interventions to reduce rates of attrition.
Keywords. HIV; ART outcomes; loss to follow-up; retention; attrition.
The successful global scale-up of antiretroviral therapy
(ART) programs has vastly changed outcomes for pa-
tients infected with human immunodeﬁciency virus
(HIV) throughout sub-Saharan Africa (SSA), shifting
the disease from one that was once uniformly fatal to
a chronic disease with lifelong ART. An integral factor
in redeﬁning the infection from an acute to manageable
condition is the commitment from patients that once
they are initiated on an ART regimen, they will remain
adherent. Once a patient initiates a treatment regimen,
they must return for clinical visits, laboratory tests, pre-
scription reﬁlls, and counseling services. Oftentimes,
these requirements become burdensome, and patients
discontinue services, creating a major challenge for
most HIV treatment programs.
With approximately 168 million inhabitants, Nigeria
is the most populous country in SSA and has main-
tained an HIV prevalence of approximately 4% for
the past 6 years [1–3]. The government of Nigeria initi-
ated its National ART Program in 2001 and later gained
support from the President’s Emergency Plan For AIDS
Relief (PEPFAR) and other international donor agen-
cies in mid-2000s. From 2004 to 2012, the Harvard
School of Public Health partnered with the AIDS Pre-
vention Initiative in Nigeria (APIN) to use PEPFAR
funding provided through the US Health Resources
and Service Administration (HRSA) to scale up HIV
prevention, care, and treatment activities across Nigeria.
The scale-up of HIV care has been a major success.
However, the need to initiate over a million additional
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patients on ART, while retaining those already on therapy de-
spite tightening budgets, represents a signiﬁcant challenge; thus,
cost-effective markers for developing and monitoring targeted
interventions are needed.
Rates and predictors of LTFU have been evaluated in numer-
ous HIV programs, and rates range from 0.3% to 50% [4–18].
Although the studies differ on identiﬁed predictors of LTFU, the
majority focus on demographic and baseline measures taken
prior to ART initiation and do not evaluate predictors in a
time-dependent fashion [17,18]. The goal of this evaluation
was to use data from the Harvard/APIN PEPFAR program,
along with statistical methods that incorporate time-dependent
factors, thus building upon existing information on baseline
predictors of LTFU already in the literature; the hypothesis
was that adherence patterns, CD4+ cell counts and viral loads
(VLs) would be strong indicators of risk of LTFU in a time-
dependent manner. The ultimate goal in addressing this
hypothesis was to identify an easy and inexpensive method
for healthcare works challenged with limited resources and
high patient volumes to identify candidates for targeted inter-
ventions to improve retention.
METHODS
Patients
Upon entry into the Harvard/APIN PEPFAR HIV care pro-
gram and following informed consent, all patients were assessed
for ART eligibility according to Nigerian National Guidelines,
which followed the WHO guidelines [19,20]. All consent
forms were approved by the institutional review boards at Har-
vard, APIN, and all the corresponding Harvard/APIN PEPFAR
HIV care and treatment sites. All ART-eligible patients were
placed on ART following a clinical examination and a set of
baseline laboratory tests, which included hematology, clinical
chemistries, CD4+ cell count, and VL enumeration. Patients
were generally given a 30-day supply of antiretroviral (ARV)
medications. Following the ﬁrst prescription pick-up, reﬁlls
were obtained on a monthly basis. Following the initiation of
ART, laboratory tests were repeated every 6 months unless an
earlier evaluation was medically necessary. All patient data
were maintained in electronic databases.
For the analyses, we included patients who were enrolled on
ART between June 2004 and February 2011 to ensure at least 1
year of follow-up time for the evaluation. All patients were at
least 15 years of age at enrollment. Patients who had previous
ARV experience prior to enrolling in the Harvard/APIN pro-
gram were excluded.
Deﬁnition of Loss to Follow-Up
Patients were classiﬁed as LTFU if, at the time of interest, at least
2 months had elapsed since the patient’s last scheduled pick-up
date and they did not later return. Patients who died, withdrew,
or transferred to non-Harvard/APIN sites during the period of
evaluation were not considered LTFU.
Factors Associated With LTFU
We evaluated baseline demographic (age, sex, education, occu-
pation type, enrollment site, enrollment year, and HIV trans-
mission category) and clinical (hepatitis B virus [HBV] and/
or hepatitis C virus [HCV] coinfection at enrollment, WHO
clinical stage, ART regimen, CD4+ cell count, and VL) factors,
where baseline is deﬁned as at the time of ART initiation. For
analyses, age was converted to a categorical variable based on
quartiles, and the occupation category was collapsed into
non-income-generating (ie, unemployed, students, job appli-
cants, housewives/homemakers, and retirees) and income-
generating (laborer vs professional) categories. Additionally,
we incorporated time-dependent factors into the analyses, in-
cluding adherence patterns during the ﬁrst 3 months of treat-
ment, CD4+ cell count, and VL.
Measurement of Adherence
To evaluate the time-speciﬁc association between adherence
and LTFU, we focused on adherence patterns during the ﬁrst
3 months of ART to determine whether the pattern was predic-
tive of LTFU by month 12. For these subset evaluations, we ex-
cluded patients that discontinued during the ﬁrst 3 months of
treatment in order to avoid biasing values with those who had
poor adherence during early treatment.
We used prescription reﬁll timeliness as the measurement of
adherence, which has been previously shown in multiple studies
to be a strong surrogate [21–26]. To compute pill coverage for
the ﬁrst 90 days of treatment, we divided the total number of
pills supplied for the time period by 90 and then multiplied
by 100 for an average percent adherence during the time period.
Average percent adherence values were collapsed into categories
for analyses.
Statistical Analyses
Univariate comparisons categorical variables were performed
using the χ2 or Fisher exact test; Student t-test was used for nor-
mally distributed continuous variables and the Wilcoxon rank
sum test for non-normally distributed continuous variables.
Statistical signiﬁcance was deﬁned at an α-level of 0.05. Cate-
gorical variables were collapsed based on results of univariate
analyses.
Kaplan-Meier analyses were used to examine the probability
of follow-up for patients that initiated ART between June 2004
and February 2011. Patients were considered at risk of LTFU
from the time they initiated ART to the date of their last
pick-up, transfer, withdrawal, or death. Patients who withdrew
or transferred were censored at the date of their last pick-up,
and patients who died were censored at the time of their
death. Cox proportional hazards models were used to evaluate
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baseline and demographic factors associated with LTFU.
Unmeasured heterogeneity between sites was controlled in
the models by using random effects methods. Additionally,
clinically relevant interaction terms were tested as potentially
explanatory of signiﬁcant ﬁndings. To address potential bias
due to patients who were excluded because of missing data,
multiple imputation of missing values were performed using
chained equations assuming missing at random and 10 imputed
data sets.
To further evaluate the time-dependent association between
CD4+ cell counts and risk of LTFU, we examined LTFU in year-
ly increments following ART initiation, starting with the second
pick-up for the CD4+ cell count. For the ﬁrst time point (ie,
“after visit 1”), we compared median baseline CD4+ cell counts
of those who were lost following the ﬁrst visit to those who were
retained beyond the ﬁrst visit. For each subsequent time point
(ie, months 12, 24, 36, and 48), we compared median CD4+ cell
counts from the visit 6 months prior to determine if it was pre-
dictive of LTFU or retention by the noted time point. To exam-
ine the time-dependent association between VL and LTFU, we
similarly analyzed retention at months 12, 24, 36, and 48 and
compared VL suppression rates at the visit 6 months prior to
determine if suppression was predictive of LTFU. For both
the CD4+ cell count and VL evaluations, each time point con-
tained data from those patients retained in the prior time point;
patients who transferred, withdrew, or died in the prior time pe-
riod were removed from subsequent cohorts.
To determine whether the relationships between CD4+ cell
counts and viral loads with LTFU rates remained after adjusting
for other predictors of LTFU, we generated random effects Cox
proportional hazard models including CD4+ cell counts and
viral load suppression as time-varying covariates, while control-
ling for all other signiﬁcant baseline and demographic pre-
dictors of LTFU. Values for the Cox models were generated
using both complete cases and multiply imputed data. Multiple
imputations for time-dependent data were generated using a
2-fold fully conditional speciﬁcation algorithm for imputation
of missing longitudinal data.
For the subanalysis on the association between adherence pat-
terns during the ﬁrst 3 months of treatment and subsequent risk
of LTFU by month 12, we generated a random effects logistic re-
gression model to examine predictors of loss, controlling for site
variability. Signiﬁcant predictors of LTFU from the Kaplan-
Meier analyses were retained in the model regardless of statistical
signiﬁcance as they were shown to be signiﬁcant predictors of
LTFU when all patients were evaluated. All statistical analyses
were conducted using Stata version 13 (College Station, TX).
RESULTS
Between June 2004 and February 2012, 88 983 adult patients
initiated standard ﬁrst-line (1L) ART at one of 32 hospitals
(10 tertiary and 22 secondary) spread across 9 states supported
by the Harvard/APIN PEPAR program. Of those patients,
88 665 (99%) were HIV-1 monoinfected. In order to concen-
trate our analyses on patients with at least 1 year since ART ini-
tiation, we focused on the 72 770 patients enrolled as of
February 2011. Of those patients, we excluded 15 394 who
were ARV-experienced at enrollment (Fig. 1).
Of the total 57 376 ARV-naive patients enrolled by February
2011, 4980 (8.7%) were LTFU, 350 died (0.6%), and 93 (0.2%)
transferred or withdrew following the ﬁrst drug pick-up. After
comparing patients who did not return after ﬁlling their ﬁrst
prescription to those who returned for at least 1 reﬁll and ﬁnd-
ing these groups to be very different, we also excluded patients
who did not return after ﬁlling their ﬁrst prescription (Table 1).
Of the 51 953 patients enrolled by February 2011, 14 626
(28%) were LTFU, 816 (2%) died, and 1515 (3%) were reported
as transferred or withdrawn following the second drug pick-up
as of March 2012. The majority of the lost patients generally dis-
continued within the ﬁrst 12–18 months following initiation of
ART. When combining data across enrollment years, the reten-
tion rates were 91% following the ﬁrst pick-up, 79% by month 6,
74% by month 12, and 70% by month 18. In evaluating the total
percentage lost by time on treatment and year of ART initiation,
these rates varied by enrollment year, where loss by month 12
appeared greater for the cohorts enrolled after 2006 as com-
pared to those enrolled between 2004 and 2006.
Overall, of the ARV-naive patients with at least 1 prescription
reﬁll, 65% were female, 57% had a secondary or tertiary level
education, 58% were married, and 75% had income-generating
occupations. The median age for the cohort was 35 years (inter-
quartile range [IQR]: 29-41). At baseline, the majority (67%) of
patients had a CD4+ cell count of >100 cells/mL. In addition,
78% of patients had a baseline viral load of >10 000 copies/
mL, and 22% had tuberculosis coinfection, 16% were HBsAg
positive, and 6% HCV antibody positive.
Baseline Predictors of LTFU
In preliminary adjusted random effects Cox proportional haz-
ard modeling of baseline predictors, controlling for site differ-
ences, the factors associated with increased risk for LTFU in the
51 953 patients that made at least 1 reﬁll pick-up were: lower
age; being male; initiating ART during or after 2006; having
non-income-generating occupations or no education; being
single, divorced, or separated; higher baseline WHO clinical
stage and viral load; and lower baseline CD4+ cell counts
(data not shown). Additionally, we found that patients who
started on tenofovir (TDF) + emtricitabine (FTC) or lamivu-
dine (3TC) + efavirenz (EFV) were more likely to be LTFU
than those on the zidovudine (AZT)-containing regimens
(<0.001). We tested interactions between sex and regimen as
well as ART initiation year and regimen and found that neither
was signiﬁcant in explaining model outcomes.
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CD4+ Cell Counts and Viral Suppression Rates Predict
LTFU in Time-Dependent Manner
After ﬁnding that baseline CD4+ cell count was a signiﬁcant
predictor of LTFU, we wanted to determine whether CD4+
cell count remained a continuous predictor of loss. The median
CD4+ cell counts (Fig. 2a) continually increased over the 4 years
for both of the patients who were retained, as well as those who
were not retained in the evaluated time period. For patients that
were lost, the median of the last CD4+ cell count prior to loss,
regardless of time of loss, was 183 cells/mL (IQR: 86–316 cells/
mL). At each of the assessed time points, the median CD4+ cell
count from the prior 6 months was higher in those subse-
quently retained compared to those LTFU (Fig. 2a). Similarly,
we found that retained patients were more likely to be virally
suppressed at their prior 6-month visit compared to those
who were LTFU (Fig. 2b; P < 0.05); the median VL prior to
loss in LTFU patients was 15 457 cp/mL (IQR: 200–143 386),
where nearly 71% of patients had detectable viral load within
the 6 months preceding loss regardless of time of loss.
When we adjusted for age, sex, year of ART initiation, occu-
pation type, marital status, education status, heterosexual sex as
a risk factor, WHO stage, tuberculosis at entry, and viral load
using a random effects Cox proportional hazards model that
controlled for site variability, we found that the associations be-
tween CD4+ cell count and LTFU as well as VL and LTFU, in a
time-dependent manner, remained statistically signiﬁcant
(Table 2; P < 0.001). Interestingly, the associations between
sex and LTFU as well as regimen and LTFU did not remain fol-
lowing addition of CD4+ count and VL as time-dependent var-
iables. Further, although the statistical signiﬁcance of the
associations between ART initiation year and WHO stage, re-
spectively, with LTFU changed upon imputation of missing
data, the associations between CD4+ count with LTFU and
VL with LTFU, respectively, were not affected.
Early Adherence Patterns Predict LTFU by Month 12
Post-Initiation of ART
Of the patients with at least 3 months on treatment, over half
were 100% adherent during the ﬁrst 3 months. As the largest
percentage of loss typically occurred during the ﬁrst 12 months
of treatment, we conducted a subset analysis on the 47 656 pa-
tients with at least 3 months on ART to examine the association
between adherence patterns during the ﬁrst 3 months of ART
and LTFU by month 12. In adjusted multivariate logistic regres-
sion analyses, controlling for site variability, age, sex, year of
ART initiation, occupation, marital status, education, baseline
WHO stage, baseline CD4+ cell count, baseline VL, and initial
ART regimen, the association between adherence and LTFU re-
mained, with a trend of reduced risk of LTFU with better adher-
ence during the ﬁrst 3 months of treatment. Speciﬁcally,
Fig. 1. Flow diagram for patients included in this evaluation. Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; HIV, human immunodeﬁciency virus;
1L, ﬁrst-line.
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Table 1. Demographics and Baseline Clinical Characteristics of ARV-Naive Treatment Cohort
Characteristic (a) All patients
(b) Patients discontinued
after only 1 pick-up
(c) Patients retained
after 1st pick-up
(d) P-value for
b vs c
(e) Patients LTFU
after 2nd pick-up
( f ) Patients retained
after 2nd pick-up
(g) P-value
for e vs f
N 57 376 5423 51 953 – 14 626 34 996 –
Median time on ART, months (IQR) 25.7 (10.8–43.1) 0 28.6 (14.8–44.9) <0.0001 9.3 (2.9–21.0) 36.6 (23.9–51.2) 0.0001
Median age, in years (IQR) 35 (29–41) 35 (29–41) 35 (29–41) 0.49 34 (28–41) 35 (29–41) <0.0001
Sex, n (%)
Female 36 806 (64.1) 3130 (57.7) 33 676 (64.8) <0.001 8861 (60.6) 23 307 (66.6) <0.001
Male 20 570 (35.9) 2293 (42.3) 18 277 (35.2) 5765 (39.4) 11 689 (33.4)
Site Type
Secondary 5732 (10.0) 549 (10.1) 5183 (10.0) 0.73 1108 (7.6) 3705 (10.6) >0.001
Tertiary 51 644 (90.0) 4874 (89.9) 46 770 (90.0) 13 518 (92.4) 31 291 (89.4)
ART Initiation Year
Jun 2004–Dec 2005 4814 (8.4) 386 (7.1) 4428 (8.5) <0.001 1333 (9.1) 2837 (8.1) <0.001
2006 5145 (9.0) 431 (7.9) 4714 (9.1) 1756 (12.0) 2630 (7.5)
2007 7972 (13.9) 1027 (18.9) 6945 (13.4) 2424 (16.6) 4130 (11.8)
2008 13 051 (22.7) 1297 (23.9) 11 754 (22.6) 3545 (24.2) 7706 (22.0)
2009 12 838 (22.4) 1124 (20.7) 11 714 (22.5) 3034 (20.7) 8183 (23.4)
2010–Feb 2011 13 556 (23.6) 1158 (21.4) 12 398 (23.9) 2534 (17.3) 9510 (27.2)
Education, n (%)
None 10 576 (18.8) 1155 (22.5) 9421 (18.5) <0.001 3160 (22.1) 5811 (16.9) <0.001
Primary 12 373 (22.0) 1179 (23.0) 11 194 (21.9) 3292 (23.0) 7422 (21.5)
Secondary 19 855 (35.3) 1830 (35.6) 18 025 (32.3) 4910 (34.3) 12 344 (35.8)
Tertiary 13 406 (23.9) 970 (18.9) 12 436 (24.3) 2966 (20.7) 8896 (25.8)
Marital Status, n (%)
Single 11 211 (19.8) 1127 (21.7) 10 084 (19.6) <0.001 3219 (22.3) 6398 (18.4) <0.001
Married 32 569 (57.5) 2872 (55.4) 29 697 (57.7) 7814 (54.2) 20 584 (59.2)
Divorced/Separated 1446 (10.0) 558 (10.8) 4559 (8.9) 1445 (10.0) 2902 (8.4)
Widowed 1946 (13.5) 630 (12.2) 7142 (13.9) 1945 (13.5) 4868 (14.0)
Occupation
Non-income-generating 13 891 (24.6) 1.279 (24.7) 12 612 (24.6) 0.002 3890 (27.0) 8108 (23.4) <0.001
Laborer/Service Worker 39 086 (69.1) 3628 (70.1) 35 458 (69.0) 9747 (67.7) 24 178 (69.8)
Manager/Professional 3560 (6.3) 268 (5.2) 3292 (6.4) 757 (5.3) 2377 (6.9)
HIV Risk Factor
Heterosexual Sex 50 869 (95.4) 4596 (94.9) 46 273 (95.5) 0.063 13 031 (95.8) 31 152 (95.3) 0.028
Other/multiple 2435 (4.6) 247 (5.1) 2188 (4.5) 574 (4.2) 1532 (4.7)
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Table 1 continued.
Characteristic (a) All patients
(b) Patients discontinued
after only 1 pick-up
(c) Patients retained
after 1st pick-up
(d) P-value for
b vs c
(e) Patients LTFU
after 2nd pick-up
( f ) Patients retained
after 2nd pick-up
(g) P-value
for e vs f
Baseline CD4 count, cells/mL
≤50 8938 (16.5) 1223 (26.5) 7715 (15.6) <0.001 2718 (19.6) 4544 (13.6) <0.001
51–100 9743 (18.0) 977 (21.2) 8766 (17.7) 2685 (19.4) 5586 (16.7)
101–200 20 440 (37.7) 1386 (30.1) 19 054 (38.5) 5084 (36.7) 13 193 (39.4)
>200 15 038 (27.8) 1026 (22.2) 14 012 (28.3) 3359 (24.3) 10 143 (30.3)
Baseline viral load, copies/mL
0–999 4219 (8.6) 340 (8.2) 3879 (8.6) <0.001 1083 (8.6) 2633 (8.7) <0.001
1000–9999 6750 (13.7) 489 (11.8) 6261 (13.9) 1653 (13.1) 4343 (14.3)
10 000–99 999 16 942 (34.5) 1267 (30.7) 15 675 (34.8) 4229 (33.5) 10 761 (35.4)
≥100 000 21 254 (43.2) 2033 (49.2) 19 221 (42.7) 5671 (44.9) 12 645 (41.6)
WHO Stage, n (%)
1 11 533 (23.7) 614 (16.5) 10 919 (24.3) <0.001 2412 (19.8) 8046 (26.3) <0.001
2 13 740 (28.3) 882 (23.7) 12 858 (26.7) 3150 (25.9) 9108 (29.7)
3 16 390 (33.8) 1362 (36.7) 15 028 (33.5) 4321 (35.5) 10 018 (32.7)
4 6887 (14.2) 856 (23.1) 6031 (13.5) 2300 (18.9) 3452 (11.3)
TB at Entry
Yes 12 529 (21.8) 1037 (19.1) 11 492 (22.1) <0.001 3484 (23.8) 27 595 (78.9) <0.001
No 44 847 (78.2) 4386 (80.9) 40 461 (77.9) 11 142 (76.2) 7401 (21.1)
HBV Status at Baseline
Positive 6183 (16.0) 608 (17.3) 5575 (15.8) 0.025 1828 (17.5) 3497 (15.2) <0.001
Negative 32 536 (84.0) 2912 (982.7) 29 624 (84.2) 8644 (82.5) 19 592 (84.8)
HCV Status at Baseline
Positive 2143 (5.6) 163 (4.7) 1980 (5.7) 0.015 577 (5.6) 1247 (5.5) 0.54
Negative 36 238 (94.4) 3317 (95.3) 32 921 (94.3) 9805 (94.4) 21 647 (94.5)
First-line drug regimen
TDF + XTC+ EFV 10 342 (18.0) 1245 (23.0) 9097 (17.5) <0.001 2683 (18.3) 6045 (17.3) <0.001
TDF + XTC+NVP 11 389 (19.9) 1124 (20.7) 10 265 (19.8) 2977 (20.4) 6758 (19.3)
AZT + 3TC + EFV 5319 (9.3) 536 (9.9) 4783 (9.2) 1570 (10.7) 2989 (8.5)
AZT + 3TC +NVP 26 182 (45.6) 2035 (37.5) 24 147 (46.5) 6230 (42.6) 16 894 (48.3)
d4T + 3TC + EFV 302 (0.5) 54 (1.0) 248 (0.5) 93 (0.6) 141 (0.4)
d4T + 3TC +NPV 3842 (6.7) 429 (7.9) 3413 (6.6) 1073 (7.3) 2169 (6.2)
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization.
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patients with 50%–94% adherence were at 32% lower risk (95%
conﬁdence interval [CI]: 0.61–0.76), those with 94%–99% ad-
herence were at 46% lower risk (95% CI: 0.48–0.61), and
those with 100% adherence were at 64% lower risk (95% CI:
0.32–0.40) of being LTFU by month 12, as compared to those
patients with <50% adherence during the ﬁrst 3 months of treat-
ment (Fig. 3).
DISCUSSION
To our knowledge, this evaluation is the ﬁrst to examine multi-
ple time-dependent predictors of LTFU using nearly 7.5 years of
electronically maintained patient-level data on nearly 52 000
patients. The data were captured starting at the initiation of a
rapidly scaled-up HIV treatment program. Over the course of
7 years, the activities were decentralized, moving outward
from tertiary to secondary level centers. Because data were
collected from program initiation, we were able to compare
LTFU rates from patients enrolled as early as 2004 to those
entering in 2011.
Overall retention rates in the Harvard/APIN PEPFAR pro-
gram were comparable to those reported in other studies
[4,27,28]. Similar to other studies, we also found that the major-
ity of loss occurs within the ﬁrst 12–18 months of treatment
[27–31]. Interestingly, in complete case analyses, we found
that LTFU rates were generally lower for those enrolled prior
to 2006 than after 2006. We hypothesize that LTFU might
have increased with calendar time due to the expanding nature
of the scale-up program and decentralization of care, with the
provision of services being shifted from tertiary-level sites
down to secondary and primary sites (ie, scale-up effect). In ad-
dition, with other programs also offering care and opening ad-
ditional sites, it is possible that patients moved to sites closer to
their homes. Because there was no existing mechanism to inde-
pendently track movements of patients between sites in Nigeria,
we were unable to track transfers to sites outside the Harvard/
APIN PEPFAR network. Thus, part of the decreased risk of loss
associated with calendar time might be due to undocumented
transfers. It is noteworthy, however, that the association be-
tween calendar time and LTFU did not remain following impu-
tation to time-dependent CD4+ count and VL data.
This study identiﬁed some important predictors of LTFU,
particularly those that remain continuous predictors of out-
comes over time through 4 years of observation. Because the
program included such a large study population, we were over-
powered to ﬁnd statistical signiﬁcance in the smallest difference.
However, we found that some of the differences were of notable
magnitude. Other studies have also identiﬁed lower age, marital
status, and lower baseline CD4+ cell count as predictors of
LTFU [7,8,27,30,32–37]. But to our knowledge, this is the ﬁrst
study to show that CD4+ cell count and VL suppression rates
remain predictors of LTFU in a time-dependent fashion. A
few prior studies have found a correlation with adherence pat-
terns and overall survival [11,22]. Our analysis was unique in
that we focused on early adherence pattern as a predictor of fu-
ture outcomes to show time-dependent effects.
This study has several strengths based on its evaluation of a
large HIV treatment program. First, the study had a large sam-
ple size with nearly 52 000 patients. Second, the evaluation used
electronically stored patient-level data collected at 32 hospitals
and clinics across Nigeria, thus making the results of the eval-
uation more generalizable. The data were collected starting in
2004 through February 2012, allowing for monitoring of tem-
poral trends in LTFU and predictors over a signiﬁcant period.
Additionally, with over 7.5 years of data, we were able to exam-
ine rates and predictors of long-term retention. Furthermore,
Fig. 2. CD4+ cell counts and viral loads predict LTFU in time-dependent manner. Abbreviations: ART, antiretroviral therapy; LTFU, loss to follow-up; VL,
viral load.
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Table 2. Cox Proportional Hazards Model of Time-Independent and Time-Dependent Predictors of LTFU among ART-naive Adult Patients
That Made at Least 2 ART Pick-ups (n = 51 953)
Variable
Unadjusted cox values
Adjusted cox values complete
casesa
Adjusted cox values multiple
imputationsa
HR 95% CI P-value aHR 95% CI P-value aHR 95% CI P-value
Age, years
<30 Ref – – Ref – – Ref – –
30–34 0.86 0.82–0.90 <0.001 0.81 0.66–0.98 0.036 0.8 0.70–0.91 0.001
35–40 0.83 0.79–0.87 <0.001 0.75 0.59–0.95 0.015 0.76 0.66–0.88 <0.001
>40 0.84 0.81–0.88 <0.001 0.66 0.50–0.86 0.003 0.67 0.55–0.82 <0.001
Sex
Male Ref – – Ref – – Ref – –
Female 0.82 0.79–0.85 <0.001 0.98 0.87–1.10 0.69 0.91 0.80–1.03 0.14
ART Initiation Year
Jun 2004–Dec 2005 Ref – – Ref – – Ref – –
2006 1.38 1.34–1.42 <0.001 1.24 1.11–1.37 <0.001 1.12 1.01–1.25 0.04
2007 1.41 1.37–1.45 <0.001 1.74 1.34–2.27 <0.001 1.24 0.96–1.60 0.11
2008 1.31 1.28–1.34 <0.001 1.52 1.20–1.93 0.001 1.03 0.73–1.45 0.87
2009 1.26 1.23–1.30 <0.001 1.89 1.60–2.23 <0.001 1 0.74–1.34 0.98
2010–Feb 2011 1.23 1.20–1.27 <0.001 2.12 1.58–2.86 <0.001 0.84 0.49–1.43 0.52
Site Type
Secondary Ref – –
Tertiary 1.14 1.07–1.21 <0.001
Occupation
Non-income-generating Ref – – Ref – – Ref – –
Laborer/Service Worker 0.9 0.87–0.94 <0.001 1.1 1.01–1.20 0.021 1.02 0.94–1.11 0.58
Manager/Professional 0.7 0.65–0.76 <0.001 1.23 0.97–1.57 0.093 1.22 0.99–1.51 0.07
Marital Status, n (%)
Single/Divorced/Separated Ref – – Ref – – Ref – –
Married/Widowed 0.8 0.77–0.83 <0.001 0.82 0.72–0.94 0.004 0.76 0.70–0.82 <0.001
Education, n (%)
None Ref – – Ref – – Ref – –
Primary 0.86 0.82–0.90 <0.001 0.77 0.67–0.88 <0.001 0.82 0.72–0.93 0.002
Secondary 0.78 0.75–0.82 <0.001 0.76 0.67–0.86 <0.001 0.81 0.75–0.88 <0.001
Tertiary 0.65 0.62–0.68 <0.001 0.65 0.56–0.76 <0.001 0.71 0.57–0.89 0.003
HIV Risk Factor
Heterosexual Sex Ref – – Ref – – Ref – –
Other/multiple 1.18 1.02–1.37 0.029 1.58 0.48–5.21 0.45 1.17 0.78–1.75 0.44
WHO Stage
1 Ref – – Ref – – Ref – –
2 1.11 1.05–1.17 <0.001 1.24 0.99–1.55 0.06 1.14 0.94–1.37 0.2
3 1.34 1.28–1.41 <0.001 1.24 1.01–1.51 0.04 1.21 1.04–1.40 0.013
4 1.82 1.72–1.92 <0.001 1.29 0.85–1.95 0.23 1.38 1.07–1.79 0.013
TB at Entry 1.1 1.06–1.14 <0.001
HBV at Entry 1.11 1.05–1.16 <0.001 0.97 0.81–1.16 0.77 0.95 0.83–1.08 0.39
HCV at Entry 0.94 0.86–1.02 0.15
CD4+ Cell Count, cells/mL
≤50 Ref – – Ref – – Ref – –
51–100 0.46 0.38–0.57 <0.001 0.56 0.47–0.68 <0.001 0.64 0.50–0.82 <0.001
101–200 0.25 0.21–0.30 <0.001 0.34 0.25–0.47 <0.001 0.46 0.32–0.66 <0.001
>200 0.13 0.11–0.15 <0.001 0.19 0.16–0.24 <0.001 0.25 0.19–0.33 <0.001
Undetectable Viral Load 0.31 0.28–0.34 <0.001 0.4 0.34–0.49 <0.001 0.4 0.35–0.46 <0.001
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because laboratory data were electronically collected on a pa-
tient level at 6-month intervals, we were able to look at time-
dependent variables as predictors of LTFU on an individual
patient level.
The study was limited because the program did not actively
trace all patients that were lost, which is not atypical from other
ART programs. Our study is also limited in that we did not con-
duct retrospective analyses on data regarding reasons for
Table 2 continued.
Variable
Unadjusted cox values
Adjusted cox values complete
casesa
Adjusted cox values multiple
imputationsa
HR 95% CI P-value aHR 95% CI P-value aHR 95% CI P-value
Starting ART Regimen
TDF+FTC/3TC + EFV Ref – – Ref – – Ref – –
TDF + FTC/3TC +NVP 0.92 0.87–0.97 0.002 0.86 0.63–1.17 0.34 0.88 0.69–1.13 0.31
AZT + 3TC + EFV 1 0.94–1.06 0.95 0.98 0.77–1.25 0.86 0.97 0.79–1.20 0.81
AZT + 3TC +NVP 0.79 0.76–0.83 <0.001 0.89 0.66–1.22 0.48 0.9 0.75–1.08 0.26
d4T + 3TC + EFV 1.07 0.87–1.31 0.54 1.01 0.74–1.38 0.97 0.98 0.79–1.21 0.85
d4T + 3TC +NVP 0.76 0.71–0.81 <0.001 0.73 0.37–1.42 0.35 0.83 0.60–1.15 0.26
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; FTC,emtricitabine; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; TB, tuberculosis; TDF,tenofovir; 3TC, lamivudine; WHO, World Health Organization.
a Random effects Cox proportional hazards model generated to control for site variability.
Fig. 3. Results from random effects logistic regression model with multiple imputations examining association between early adherence patterns and
LTFU by M12 post-initiation of ART. Abbreviations: ART, antiretroviral therapy; LTFU, loss to follow-up; M12, month 12.
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discontinuation. If we were able to trace and administer surveys
that solicited additional data from LTFU patients, we would
have more robust information for our clinics to improve their
patient retention rates; we anticipate that having better informa-
tion on reasons for loss would subsequently lower our LTFU
rates and potentially affect the magnitudes of associations re-
garding predictors of loss. Finally, because this analysis focused
only on ART patients and we were looking only at information
from ART initiation through time on ART, we were not looking
at additional predictors from the pre-ART phase that also might
have explained retention patterns.
Studies that traced lost patients found that up to 50% of those
cumulatively lost had actually died [5,13,38,39] and that most
deaths occurred within 30 days of the last clinical encounter
with the patient [5]. Other studies that tracked lost patients
found that some simply moved to other health facilities or
chose to take a break from treatment due to insufﬁcient funds
to attend clinic, food insecurity, difﬁculty procuring childcare,
fear of stigma, or issues with adverse effects [4,39,40]. As
such, by using the LTFU composite outcome, and due to the
fact that the program only passively collects death and transfer
information, we are underestimating those that have died or left
the program.
Various researchers have shown that developing interventions
to address speciﬁc barriers can readily address the problems and
encourage some patients to return [4]. It is our belief that using
factors predictive of loss for targeted interventions before a pa-
tient is LTFU will be particularly helpful, speciﬁcally for those
patients that are lost due to reasons other than death. For exam-
ple, understanding that early adherence patterns strongly corre-
late with future LTFU could serve as an easy trigger for targeted
adherence counseling. Furthermore, knowing that lower relative
CD4+ counts or unsuppressed VL, at any time point in treat-
ment, is predictive of loss can also serve as a powerful and sim-
ple tool for targeted interventions.
In summary, between 2004 and 2012, we found that a signiﬁ-
cant proportion of patients enrolled in the Harvard/APIN PEP-
FAR treatment program were eventually LTFU. Understanding
that CD4+ cell counts, VLs and early adherence patterns are strong
predictors of future loss will aid ART programs in identifying pa-
tients for targeted interventions to improve retention rates.
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